Clinic Software← All companies
Kano Therapeutics
Circular single-stranded DNA templates: high-fidelity, immune-quiet, scalable.
health AI/biotech medtechgene therapy
StageSeed
Raised$7.1M to $7.44M
Founded2021
Employees12
LocationCambridge, MA
Business modelB2B, SaaS-like platform and partnership model (integrated DNA supply from discovery through GMP)
About
Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them.
Product
- Value proposition
- Kano provides circular single-stranded DNA (cssDNA) as a versatile, scalable genetic payload platform for cell and gene therapy, enabling precise editing, superior persistence, in vivo safety, and compatibility across delivery modalities and therapeutic approaches.
- Target customers
- biopharma and cell/gene therapy developers seeking dna payloads and integrated supply
Founders
- Floris Engelhardt — Co-founder, CEO
- John Vroom — Co-founder
- Mark Bathe — Co-founder, Professor of biological engineering
Categories
Products
cssDNA (circular single-stranded DNA) platformDNA payloads for gene therapyKanoDNA payload platformpartnered DNA supply and integration solutions
Key features
Circular ssDNA payloadshigh-fidelity editing templatesimmune-quiet topologyscalable fermentation-based productionintegration across discovery to GMPone integrated partnership for DNA supply
Technologies
circular ssDNA (cssDNA)fermentation-based manufacturingsite-specific genome editingCRISPR/nuclease compatibilityrecombinase/transposon toolsnon-integrating DNA templates
Integrations
EHR integrations are not applicableplatform integrations with therapeutic pipelines (discovery to GMP)
Target conditions
Gene therapiesCAR-Tgenetic disease therapiesgenome editing applications
Care settings
research laboratoryclinical developmentGMP manufacturing environments
Partnerships
Integrated DNA payload platform partnershipsevaluation agreements leading to full partnerships
Traction metrics
Massachusetts Manufacturing Innovation Initiative (M2I2) grant recipient
Competitors
other DNA payload providers and gene editing platforms (not listed)
Investors
Engine VenturesVsquared VenturesMetaplanetTaihill VentureZAKA VenturesLaunchpad Venture GroupTermeer InstituteAcre Venture PartnersBIG Idea VenturesPrelude VenturesRefactor CapitalSOSV
News
- A better DNA material for genetic medicine | MIT News · 2025-12-12T00:00:00.000Z
- Kano Therapeutics: Funding, Team & Investors | Startup Intros · 2026-04-16T00:00:00.000Z
- Kano Therapeutics 2026 Company Profile - PitchBook · 2024-08-12T00:00:00.000Z
- Kano Therapeutics Secures $7.1M to Bring Targeted, Non-Viral DNA Insertion Technology to Genetic Medicine · 2024-08-12T00:00:00.000Z
- Exclusive: MIT spinout launches with focus on improving DNA... · 2024-08-09T00:00:00.000Z
